Two different strategies, which aim at alleviating mechanism-mediated side effects but preserving or improving an overall efficacy profile in T2DM, have been executed in the identification of new generations of synthetic PPAR ligands. The gene discussed is PPARA; the disease is type 2 diabetes mellitus.